Many drugs, few innovations in psychiatric drug classes

08/20/2013 | New York Times (tiered subscription model), The

Most of the drugs in each class for mental illness work by similar mechanisms, some have intolerable side effects or fail to elicit a response in many patients, and few drugs have been developed since the 1950s that aim for different molecular targets, writes Dr. Richard Friedman, a professor of clinical psychiatry at Weill Cornell Medical College. Drugmakers have shown little interest in pursuing innovative psychiatric drugs in part because the roots of most psychiatric disorders have not been identified, Friedman writes. Recently, however, academic researchers have been engaging in large-scale projects to understand the human brain in an effort to identify the circuits and genes involved in psychiatric disorders and find promising new targets for drugs, Friedman writes.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC